跳至主要内容
临床试验/NCT02375126
NCT02375126Unknown不适用

Normal Quantitative EEG (qEEG) Dataset for the Use in Comparison With Patients Suffering Carbon Monoxide (CO) Poisoning

Intermountain Health Care, Inc.1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2014年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
80
试验地点
1
主要终点
Electroencephalography Completion Questionnaire (Y/N)

研究概览

简要总结

In this study, the investigators will collect EEG data in normal, healthy volunteers without a history of prior brain injury. This data will be analyzed by computer (quantitative, or qEEG) and stored in a normative database so that, in the future, the investigators can better understand and characterize the brain damage that can result from carbon monoxide (CO) poisoning and other types of brain injury.

详细描述

This is a pilot, prospective, non-comparative, non-invasive, minimal risk research study to obtain qEEG data on normal, healthy individuals to include in a normal control database for use in comparison with patients with CO poisoning and other types of brain injury. The use of anti-depressant medication use is relatively common in the general adult population. There is varying opinion whether anti-depressant medication alters an otherwise normal clinical EEG. We have included healthy individuals taking anti-depressant medication to determine if those medications influence the EEG. The EEG data will be collected, analyzed, and stored for use in future research studies and for clinical care. Evaluating patients with qEEG methodology may assist in diagnosis and treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women, from 18 to 55 years old at the time of study enrollment. Women who are greater than 6 weeks post-partum, who are breastfeeding are allowed to participate if they are able to finish the electroencephalography (EEG) without interruption.
  • Able to speak and read English as their primary language.
  • Agrees to, and appears able to, participate in all outcome assessments.
  • Demonstrates the ability to offer informed consent and signs the study informed consent document.

排除标准

  • Vulnerable populations including, prisoners, pregnant women, and minors.
  • Women who are less than 6 weeks post-partum.
  • Unwilling or unable to participate in planned study visits.
  • Any past history of brain injury due to trauma, surgery, hypoxia, infection, inflammation, toxicity (e. g., carbon monoxide poisoning), or cerebrovascular etiology.
  • Individuals with a diagnosis of, or a persistent history of, or symptoms of a neurological disorder (e.g., tinnitus, vertigo, chronic fatigue, numbness, tingling, chronic migraine, fibromyalgia, multiple sclerosis).
  • Currently undergoing therapy for affective disorders, behavioral disorders, or psychological disorders.
  • Diagnosis of post-traumatic stress disorder or sub-clinical post-traumatic stress symptoms.
  • Diagnosis of diabetes mellitus, type 1 and type
  • Current complaints of brain injury symptoms such as cognitive or affective problems.
  • Known neuroimaging abnormalities.
  • Participants taking daily prescription drugs or oral over the counter medications beyond vitamins that could impact a normal outcome determined by the Principal Investigator (e.g., beta blockers).
  • Participants who are ≥45 may be taking statins or angiotensin converting enzyme (ACE) inhibitors.
  • Participants between the ages of 18-55 may be taking antidepressants indicated for depression or post-partum depression.
  • Oral or injectable contraceptives are permitted
  • Known atrial septal defect, including but not limited to patent foramen ovale.
  • History of bypass surgery.
  • History of hydrocephalus/microcephaly/macrocephaly.
  • History of developmental delay or learning disorder as a child.
  • Previous or current use of any illicit drug, at any age.
  • Current positive urine drug test for any illicit substance.
  • History, by self-report in the last year, of alcohol abuse.
  • Current or previous tobacco use, with the exception of minimal use during adolescence.
  • Use of any assistive hearing device, or unable to verbally communicate due to hearing loss.
  • History, by self-report, of receiving chemotherapy drugs or therapeutic ionizing radiation to the head.
  • Foreign material in the head.
  • Active malignancy or prior malignancy (except basal cell carcinoma) within the last 5 years.
  • Unable to abstain from caffeine products for at least a 2 hour interval.

结局指标

主要结局

Electroencephalography Completion Questionnaire (Y/N)

时间窗: Baseline

Electroencephalography study completed for the participant. (Y/N)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Normal Quantitative EEG (qEEG) Dataset | 临床试验